These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1845043)

  • 41. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Live attenuated SIV vaccines are not effective in a postexposure vaccination model.
    Linhart H; Gundlach BR; Sopper S; Dittmer U; Mätz-Rensing K; Kuhn EM; Müller J; Hunsmann G; Stahl-Hennig C; Uberla K
    AIDS Res Hum Retroviruses; 1997 May; 13(7):593-9. PubMed ID: 9135877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
    Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
    Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys.
    Murphey-Corb M; Montelaro RC; Miller MA; West M; Martin LN; Davison-Fairburn B; Ohkawa S; Baskin GB; Zhang JY; Miller GB
    AIDS; 1991 Jun; 5(6):655-62. PubMed ID: 1883540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
    Leno M; Carter L; Venzon DJ; Romano J; Markham PD; Limbach K; Tartaglia J; Paoletti E; Benson J; Franchini G; Robert-Guroff M
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):461-70. PubMed ID: 10195756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques.
    Kent SJ; De Rose R; Mokhonov VV; Mokhonova EI; Fernandez CS; Alcantara S; Rollman E; Mason RD; Loh L; Peut V; Reece JC; Wang XJ; Wilson KM; Suhrbier A; Khromykh A
    Virology; 2008 May; 374(2):528-34. PubMed ID: 18272194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Attenuated retrovirus vaccines and AIDS.
    Van Rompay KK; Spinner A; Otsyula M; McChesney MB; Marthas ML
    Science; 1995 Nov; 270(5239):1218-9; author reply 1220-2. PubMed ID: 7502051
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques.
    Malkevitch N; Rohne D; Pinczewski J; Aldrich K; Kalyanaraman VS; Letvin NL; Robert-Guroff M
    AIDS Res Hum Retroviruses; 2004 Feb; 20(2):235-44. PubMed ID: 15018712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Candidate vaccines protect macaques against primate immunodeficiency viruses.
    Stott J; Hu SL; Almond N
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stimulation of specific immune responses to simian immunodeficiency virus using chimeric hepatitis B core antigen particles.
    Yon J; Rud E; Corcoran T; Kent K; Rowlands D; Clarke B
    J Gen Virol; 1992 Oct; 73 ( Pt 10)():2569-75. PubMed ID: 1402801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modern vaccines. Human immunodeficiency virus and AIDS: challenges and progress.
    Schild GC; Minor PD
    Lancet; 1990 May; 335(8697):1081-4. PubMed ID: 1970381
    [No Abstract]   [Full Text] [Related]  

  • 53. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
    Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
    Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetically engineered vaccines for animal viral diseases.
    Yilma T
    J Am Vet Med Assoc; 1994 May; 204(10):1606-15. PubMed ID: 8050940
    [No Abstract]   [Full Text] [Related]  

  • 57. Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge.
    Wade-Evans AM; Stott J; Hanke T; Stebbings R; Berry N; Lines J; Sangster R; Silvera P; Walker B; MacManus S; Davis G; Cowie J; Arnold C; Hull R; Almond N
    AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1517-26. PubMed ID: 11709096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
    Hel Z; Tsai WP; Thornton A; Nacsa J; Giuliani L; Tryniszewska E; Poudyal M; Venzon D; Wang X; Altman J; Watkins DI; Lu W; von Gegerfelt A; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
    J Immunol; 2001 Dec; 167(12):7180-91. PubMed ID: 11739541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239.
    Evans DT; Bricker JE; Sanford HB; Lang S; Carville A; Richardson BA; Piatak M; Lifson JD; Mansfield KG; Desrosiers RC
    J Virol; 2005 Jun; 79(12):7707-20. PubMed ID: 15919923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques.
    Abel K; La Franco-Scheuch L; Rourke T; Ma ZM; De Silva V; Fallert B; Beckett L; Reinhart TA; Miller CJ
    J Virol; 2004 Jan; 78(2):841-54. PubMed ID: 14694116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.